Get started
Author

Lukas Burghart

Observed names: L Burghart, L. Burghart
Observed institutions: Sigmund Freud Privatuniversität Wien, University of Vienna, Vienna General Hospital, Wilhelminen Hospital, Wiener Krankenanstaltenverbund, Medical University of Vienna, Pomeranian Medical University
ORCID: 0000-0003-3763-8473
Observed ORCIDs: 0000-0003-3763-8473, 0000-0002-9867-9829
OpenAlex ID: A5089129516
Empagliflozin in posttransplantation diabetes mellitus: A prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety
2018 · Elisabeth Schwaiger, Lukas Burghart, et al. · American Journal of Transplantation · 136
Imaging features facilitate diagnosis of porto-sinusoidal vascular disorder
2022 · Katharina Lampichler, Georg Semmler, et al. · European Radiology · 38
PDF
Evaluation of potential hepatic recompensation criteria in patients with PBC and decompensated cirrhosis
2024 · Benedikt Silvester Hofer, Lukas Burghart, et al. · Alimentary Pharmacology & Therapeutics · 36
Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure
2024 · Georg Semmler, Sonia Alonso López, et al. · Journal of Hepatology · 35
Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis
2021 · Lukas Burghart, Emina Halilbasic, et al. · Journal of Gastroenterology · 32
PDF
Incidence and Clinical Significance of Recompensation After HCV Cure
2025 · Georg Semmler, Sabela Lens, et al. · Clinical Gastroenterology and Hepatology · 24
PDF
Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure
2024 · Georg Semmler, Sonia Alonso López, et al. · Hepatology · 20
Late-stage presentation with decompensated cirrhosis is alarmingly common but successful etiologic therapy allows for favorable clinical outcomes
2023 · Michael Schwarz, Caroline Schwarz, et al. · PLoS ONE · 14
PDF
HCV hotline facilitates Hepatitis C elimination during the COVID ‐19 pandemic
2022 · Lukas Hartl, Mathias Jachs, et al. · Journal of Viral Hepatitis · 11
PDF
Portal hypertension and its prognostic implications in patients with Wilson's disease
2024 · Lukas Burghart, Peter Ferenci, et al. · Alimentary Pharmacology & Therapeutics · 10
PDF
A systematic PCR record‐based re‐call of HCV ‐ RNA ‐positive people enables re‐linkage to care and HCV elimination in Austria — The ELIMINATE project
2024 · Lorenz Balcar, Michael Schwarz, et al. · Liver International · 6
PDF
Combining treatment for chronic hepatitis C with opioid agonist therapy is an effective microelimination strategy for people who inject drugs with high risk of non-adherence to direct-acting antiviral therapy
2023 · M. Schwarz, C. Schwarz, et al. · Journal of Virus Eradication · 5
Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis
2025 · Lukas Burghart, Sonja Treiber, et al. · Alimentary Pharmacology & Therapeutics · 4
PDF
Extending the Baveno VII definition of recompensation to autoimmune hepatitis: Considerations regarding treatment timing and response criteria
2025 · Benedikt S. Hofer, Lukas Burghart, et al. · JHEP Reports · 3
PDF
ELIMINATE: a PCR record-based macroelimination project for systematic recall of HCV-RNA-positive persons in Austria
2023 · Caroline Schwarz, David Bauer, et al. · Wiener klinische Wochenschrift · 3
PDF
THU-183-YI Immunosuppressive treatment facilitates hepatic recompensation in patients with decompensated cirrhosis due to autoimmune hepatitis-a pilot study
2024 · Benedikt Hofer, Lukas Burghart, et al. · Journal of Hepatology · 1
Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis—Authors' reply
2024 · Lukas Burghart, Benedikt Silvester Hofer, et al. · Alimentary Pharmacology & Therapeutics · 1
PDF
Editorial: Recompensation in PBC is good. But is it good enough? Authors' reply
2024 · Benedikt Silvester Hofer, Lukas Burghart, et al. · Alimentary Pharmacology & Therapeutics · 1
Validation and refinement of the Baveno VII criteria for risk stratification in compensated advanced chronic liver disease after HCV-cure
2023 · Georg Semmler, Sonia Alonso Lopez, et al. · Journal of Hepatology · 1
The risks of first hepatic decompensation and HCC remain constant during long-term follow-up and can be stratified by a one-time assessment after HCV-cure
2023 · Georg Semmler, Sonia Alonso Lopez, et al. · Journal of Hepatology · 1
Austrian Society of Gastroenterology and Hepatology (ÖGGH) consensus on primary biliary cholangitis
2026 · Emina Halilbasic, Elisabeth Tatscher, et al. · Wiener klinische Wochenschrift
PDF
Letter on ‘Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis’: Authors' Reply
2026 · Lukas Burghart, Thomas Reiberger, et al. · Alimentary Pharmacology & Therapeutics
PDF
A liberalized approach to directly observed therapy for HCV retains excellent cure rates among PWID in Vienna
2025 · Caroline Schwarz, Angelika Schütz, et al. · Journal of Virus Eradication
THU-288 Prognostic value of liver stiffness dynamics in patients with autoimmune hepatitis
2025 · Lukas Burghart, Sonja Treiber, et al. · Journal of Hepatology
WED-198 Incidence and clinical significance of recompensation after HCV- cure
2025 · Georg Semmler, Sabela Lens, et al. · Journal of Hepatology
Works count: 45
Citation count: 382
H-index: 10
I10-index: 10
Year
Topic
Type